CEL-SCI Co. (NYSEAMERICAN:CVM) insider Eyal Talor sold 8,192 shares of CEL-SCI stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $2.06, for a total value of $16,875.52. Following the transaction, the insider now directly owns 117,698 shares of the company’s stock, valued at $242,457.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Eyal Talor also recently made the following trade(s):
- On Friday, January 12th, Eyal Talor sold 101 shares of CEL-SCI stock. The shares were sold at an average price of $2.15, for a total value of $217.15.
- On Tuesday, January 16th, Eyal Talor sold 1,808 shares of CEL-SCI stock. The shares were sold at an average price of $2.15, for a total value of $3,887.20.
Shares of CEL-SCI Co. (NYSEAMERICAN:CVM) traded up $0.07 during mid-day trading on Wednesday, reaching $1.82. The company had a trading volume of 80,226 shares, compared to its average volume of 267,959. The firm has a market capitalization of $21.77, a price-to-earnings ratio of -1.12 and a beta of -1.49. CEL-SCI Co. has a 1 year low of $1.46 and a 1 year high of $4.00.
CEL-SCI (NYSEAMERICAN:CVM) last announced its quarterly earnings data on Monday, February 12th. The company reported ($0.53) EPS for the quarter. The company had revenue of $0.11 million during the quarter.
TRADEMARK VIOLATION WARNING: “Insider Selling: CEL-SCI Co. (NYSEAMERICAN:CVM) Insider Sells 8,192 Shares of Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/cel-sci-co-cvm-insider-eyal-talor-sells-8192-shares.html.
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.